Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
about
The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.A summary of the second annual HIV Microbiome workshop.Bugs, drugs, and HIV: the role of the vaginal microbiome in HIV risk and antiretroviral efficacy for HIV prevention.A microbiome variable in the HIV-prevention equation.The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.Converging epidemics of sexually transmitted infections and bacterial vaginosis in southern African female adolescents at risk of HIV.Impact of antiretroviral drugs on the microbiome: unknown answers to important questions.Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.Defining the barriers to women publishing in high-impact journals.Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father.The microbiome and HIV persistence: implications for viral remission and cure.Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.Vaginal microbiota and susceptibility to HIV.Maximizing the Benefits of HIV Preexposure Prophylaxis.Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA.Current status of the HIV epidemic & challenges in prevention.Sex Differences in HIV Infection.Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.Microbiota transplantation: concept, methodology and strategy for its modernization.Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.Prevalence of sexually transmitted infections among young people in South Africa: A nested survey in a health and demographic surveillance site.Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.CROI 2018: Epidemic Trends and Advances in HIV Prevention.Role of Porphyromonas gingivalis outer membrane vesicles in oral mucosal transmission of HIV.Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naive macaquesUsing safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tractSex Differences in HIV Infection: Mystique Versus MachismoVaginal washing and lubrication among female sex workers in the Mexico-US border region: implications for the development of vaginal PrEP for HIV preventionHIV and sexually transmitted infections: responding to the "newest normal"FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovirGut bacteria can stop cancer drugs from working
P2860
Q38641903-0AD9CB2F-1A49-4647-BDFF-087CC7D41FF7Q40045238-ED5A27A2-7EB0-4647-A417-7869012D9490Q40089643-E1D893DD-9608-4FA7-A384-E59B079FD901Q40188578-7BAC0B8B-A190-4161-8D0A-44DB830549D5Q45326390-2668A122-DD93-4125-A505-9E10FC6FFC92Q46243938-BA2B4E63-592F-4C10-8F70-7107D7519638Q46286824-3E4A0A96-8425-4791-BDEA-D275AB6A85CAQ47151161-79EE26BC-96D9-490D-88EE-E005A0F57175Q47549352-8FEF53B8-B01D-4F2D-8CC7-2FA782AB4823Q47550799-DE719FF9-847D-482A-96FB-7EA3CE5C0D31Q47580980-AED49A29-93FD-4A4D-80C4-4CF909C7FBE4Q49926142-8973690C-99FC-4731-B7EB-C8C2ED303034Q50101300-A289148B-81C3-49E7-B7C8-34A625F8FC4AQ52566642-059A5070-4327-47FB-9366-757C6525BDC5Q52571192-D6D00D19-CC98-480F-A7EB-000A3BF1D83EQ52583525-255BE8D1-B50F-49A9-A2E9-3E141F91E8E1Q52674721-1C819724-185A-4242-9F73-1F205D934F5FQ52685409-F0C3555C-C8BF-4688-B917-2E9879F54EE6Q52716963-416C6F52-7A50-4B62-A332-2D2CDEA14554Q53681301-9219D173-F8B2-4100-A221-36D7FB215DF0Q53701932-02D5260D-9201-4009-9583-9412C9925E89Q55026569-EBC65164-DAD9-4D16-A74E-24DA1726C8FFQ55231881-77FC4AD9-1748-4171-8D1A-593F8C195DCEQ55353681-2124D18D-E570-499E-AF59-71715E3D77C8Q55514511-0BD44F5C-B860-4B88-BC1E-C4212A1C3368Q56518070-A32EB1EA-33E2-4553-A380-6CC29D710182Q56978353-8E169EB6-C810-449F-8B45-D00159CB174BQ56996082-39D94214-6B93-4A9E-91B1-DD1514F40991Q57169396-A28BB96E-1FDE-418D-9228-B12B68E27BA6Q57613821-9CD5248B-F755-4098-8C3A-E5178A1EF788Q58787428-F6B87272-C084-47EB-8CCB-4CE8F5BBB6B3Q74441218-39D642B3-3400-4E3F-9414-D332C88916FB
P2860
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
@en
type
label
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
@en
prefLabel
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
@en
P2093
P2860
P50
P356
P1433
P1476
Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.
@en
P2093
Alexander S Zevin
Jennifer Butler
Laura Noël-Romas
Michelle Perner
P2860
P304
P356
10.1126/SCIENCE.AAI9383
P407
P50
P577
2017-06-01T00:00:00Z